Get the Stockscreener App
0.2636
1.31%
0.0034
After Hours:
.27
0.0064
+2.43%
AEON Biopharma Inc. stock is traded at $0.2636, with a volume of 564.51K.
It is up +1.31% in the last 24 hours and up +24.40% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$0.2602
Open:
$0.2621
24h Volume:
564.51K
Relative Volume:
0.09
Market Cap:
$13.15M
Revenue:
-
Net Income/Loss:
$-60.11M
P/E Ratio:
-0.0606
EPS:
-4.347
Net Cash Flow:
$-12.04M
1W Performance:
+8.70%
1M Performance:
+24.40%
6M Performance:
-74.16%
1Y Performance:
-66.15%
1-Day Range:
$0.2575
$0.2705
1-Week Range:
$0.2426
$0.2849
52-Week Range:
$0.1772
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.2636 | 13.15M | 0 | -60.11M | -12.04M | -4.347 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
Live AEON Biopharma, Inc. (AEON) Technical Analysis - Traders Union
AEON Biopharma (AEON) Ticks Up to $0.26 as Sub-$1 Micro-Cap Defends $0.25 SupportSkew Index - siam.in
$AEON Biopharma (AEON.US)$ following choch - Moomoo
AEON Q2 2026 Earnings: Narrower-Than-Expected Loss, Yet Stock SlidesEPS Guidance Update - careplusvn.com
AEON Biopharma, Inc. Stock Price Today | AEON Live Chart & News - Traders Union
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
$AEON Biopharma (AEON.US)$ 1 choch, 2 choch, last major choch almost ✔️ and consolidation over. - Moomoo
$AEON Biopharma (AEON.US)$ - Moomoo
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Biotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slide - RTTNews
$AEON Biopharma (AEON.US)$ interesting. got it marked from 2025 not sure why lmao - Moomoo
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
The rocket is about to launch 😘 - Moomoo
Laidlaw initiates Aeon Biopharma stock coverage with buy rating By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
$AEON Biopharma (AEON.US)$ goshhh.. 😅 - Moomoo
Aeon Claims Drug Holds Up Against Botox in Stress Test - Orange County Business Journal
AEON Biopharma, Inc. Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of Abp-450 to Botox - marketscreener.com
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX - marketscreener.com
BOTOX and ABP-450 each fell to about half strength by day 14 - Stock Titan
Laidlaw initiates Aeon Biopharma stock coverage with buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference - The Manila Times
AEON Biopharma to Host Investor Meetings at Lake Street Capital Markets’ 10th Annual BIG10 Conference - quiverquant.com
AEON Biopharma (AEON) Surges 6.91% to $0.31, Nears Key Resistance at $0.33Low Volatility Picks - dars.gov.et
AEON Q2 2026 Earnings: Clinical-Stage Biotech Delivers Narrow EPS BeatFinancial Data - dars.gov.et
Insider Purchase: 10% Owner at $AEON Buys 1,150,000 Shares - Moomoo
AEON Biopharma names Paul Lee as acting chief regulatory officer By Investing.com - Investing.com Nigeria
AEON Biopharma names Paul Lee as acting chief regulatory officer - Investing.com
AEON (AEON) Price: Moves 0.52% Down to $0.19 in Latest Trading; Price Levels: Price Remains Between $0.18 Support and $0.20 Resistance under the Current SnapshotMcClellan Oscillator - careplusvn.com
Aeon Biopharma director Timothy Lynch buys $243,455 in stock By Investing.com - Investing.com India
Aeon Biopharma director Timothy Lynch buys $243,455 in stock - Investing.com
Timothy Lynch (NASDAQ: AEON) owns 13% and holds blocked warrants - Stock Titan
AEON Reports New Data on Botox Biosimilar - Orange County Business Journal
Lake Street Maintains AEON Biopharma(AEON.US) With Buy Rating, Maintains Target Price $1 - Moomoo
AEON Flat on BOTOX Developments - Baystreet.ca
META_TITLE_QUOTE - Yahoo Finance
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - The Manila Times
AEON Biopharma (AEON) Steadies at $0.28 as Key Support HoldsVolume Gap - vinanet.vn
H.C. Wainwright cuts Aeon Biopharma stock price target on dilution - Investing.com
H.C. Wainwright cuts Aeon Biopharma stock price target on dilution By Investing.com - Investing.com UK
AEON Biopharma (AEON) Holds Above $0.27 Support as Shares Edge Up 1.66%Extension Target - vinanet.vn
AEON Q4 2025 Earnings: Wider-than-Expected Loss of -$0.42 per Share as Revenue Remains Absent - vinanet.vn
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Cuts Target Price to $1.2 - Moomoo
AEON Biopharma Q2 EPS $(0.02) beats $(0.12) estimate - scanx.trade
AEON Biopharma Reports Q2 Results, Advances ABP-450 Program - TipRanks
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended - TradingView
AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AEON BIOPHARMA INC Q2 EBIT USD -5.919 MILLION - Moomoo
AEON Biopharma Inc. Stock (AEON) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Cap:
|
Volume (24h):